May 13, 2026 Oral Orforglipron Maintains Weight Loss & Cardiometabolic Benefits: A Game-Changing Oral GLP-1 Therapy
April 24, 2026 Study Reveals Harsher Judgment of Weight Loss When GLP-1 Drugs Are Used, Highlighting “Shortcut” Stigma
April 24, 2026 Study Identifies Key Risk Factors Driving MASLD Across Populations and Clinical Presentations
April 22, 2026 Title: Medicare and Medicaid Coverage of GLP-1s: CMS Initiatives to Expand Access and Lower Costs via the BALANCE Model and Other Demonstration Programs
